Navigation Links
First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

and muscle stiffness.

COPAXONE(R) is now approved in 48 countries worldwide, including the United States, Canada, Mexico, Australia, Israel, and all European countries. In Europe, COPAXONE(R) is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. In North America, COPAXONE(R) is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA). COPAXONE(R) is a registered trademark of Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

See additional important information at http://www.copaxone.com/pi/index.html or call 1-800-887-8100 for electronic releases. For hardcopy releases, please see enclosed full prescribing information.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing gen
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model

Post Your Comments:
(Date:11/25/2009)...Switzerland, Nov. 25 From Novembe...ative hearing solutions, presented the second edit...using on the special needs of the older population...in aging and audiology from around the world and m...er people with hearing loss for an opportunity to ...
(Date:11/25/2009)...v.25/PRNewswire/--AMPACFineChemicalsLLC(AFC),asubs...nnouncedtodaythatitreceivedtheEnvironmentalRespons...nvironmentalSummit,sponsoredbytheCaliforniaManufac...EnvironmentalAssociation(IEA)andtheChemicalIndustr...mostprestigiousawardavailablefromallthreeorganizat...
(Date:11/25/2009)...Nov. 25 Abaxis, Inc. (Na...uring point-of-care blood analysis systems, announ...executive officer, will present at the 21st Annual..., December 2, 2009 at 2:00 p.m. ET. The conference...York City. ,, About Abaxis ,, Abaxis deve...
Breaking Medicine Technology:Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 1Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 2Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 3Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 4Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 5Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 6Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 7Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 8Reportlinker Adds Wound Care Markets 4th Edition Vol II 3A Burns Report 57992 1Reportlinker Adds Wound Care Markets 4th Edition Vol II 3A Burns Report 57992 2Reportlinker Adds Wound Care Markets 4th Edition Vol II 3A Burns Report 57992 3Democratic Governors Urge Congress to Act on Health Insurance Reform 57988 1Democratic Governors Urge Congress to Act on Health Insurance Reform 57988 2
...and NEEDHAM, Massachusetts, February 2 /PRNewswire...hange: ORIDN). During the recent annual,meeting of...n Antonio, Texas,major new findings from numerous ...al benefit of end-tidal CO2 (EtCO2) monitoring usi...ented. , Research was presented on the new Ori...
...IS, Jan. 30 In a new study, Cymbalta,(duloxetine ...erity,significantly, compared with placebo, in pat...rom the 13-week randomized, double-blind, placebo-... annual meeting of the American Academy,of Pain Me...e-treated patients showed greater reductions from ...
Other Medicine Technology:Oridion Announces Significant Medical Studies Presented at STA 2Oridion Announces Significant Medical Studies Presented at STA 3Oridion Announces Significant Medical Studies Presented at STA 4Oridion Announces Significant Medical Studies Presented at STA 5Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study 2Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study 3Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study 4Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study 5
(Date:11/27/2009)...ech firm Replikins Ltd. today issued its latest bi... It shows that the lethality of the virus has dro...rus,s current outbreak in the spring of 2009 to re....1). The H1N1 infectivity count, however, remains ...B) November 27, 2009 -- Biotech firm Replikins Ltd...
(Date:11/27/2009)... 27 The Gymboree Corpora..., CFO/COO, will present at the NASDAQ OMX 23rd Inv...Hotel in London, England, on Wednesday, December 2...ve broadcast of The Gymboree Corporation,s present...oree.com, click on "Our Company" at the bottom of ...
(Date:11/27/2009)...E, France, Nov. 27 Team Garmin-Sli...eam dedicated to ethical sporting and developing t... today that it will become Team Garmin-Transitions... sponsor of the team. Transitions Optical is the w...ffering the most advanced photochromic technology ...
(Date:11/27/2009)...Care Holdings has announced that it has become a n...f the largest nonprofit organizations dedicated to..., Delray Beach, FL (Vocus)...BB: XCHO), a company specializing in the marketing...oducts, has announced today that is has become a n...
(Date:11/27/2009)...dented medical, economic burdens, study predicts ,...he number of people with diabetes in the United St... a new study predicts. , That would bring the t... disease, up from 23.7 million today. , , At the...tes will triple, the study also warns, rising from...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3
... Organize, Navigate the,Complicated Medical, Educa...ay, the Autism,Society of America (ASA) and MeadWe...nced they have partnered to design an autism-theme... April,1., MeadWestvaco and ASA -- the nation,s l...
...,Inc. (NYSE: NUS ) chief financial officer, Ritch...r Conference in New York City on Wednesday, March,...cast live beginning at 2:30 p.m.,(EDT). Those wish...hive of the webcast will be,available at this same...
...ng immune-system killer cells with a new pair of g... Medicine of Yeshiva University transformed them i...h HIV, the virus that causes AIDS. Their novel str... new approach for combating AIDS and other viral d...
...ther healthcare professionals,to work together to ... at,risk, PARK RIDGE, Ill., March 6 - In a decisi...York in which patients were,infected with hepatiti...s across the nation to exercise the utmost,care an...
... the Iowa Chronic Care Consortium, is recognized f...Medicaid population with chronic healt...y Pharos Innovations, a,remote patient monitoring ...rough contributions in transforming the health,of ...
...ascular threats, study suggests , , THURSD...cations for rheumatoid arthritis may also be reduc...tudy suggests. , People with rheumatoid arthritis...o hardening of the arteries. Heart attack and stro...
Other Medicine News:Health News:MeadWestvaco and Autism Society of America Launch 2008 ASA Autism Awareness Cambridge Planner 2Health News:MeadWestvaco and Autism Society of America Launch 2008 ASA Autism Awareness Cambridge Planner 3Health News:Einstein researchers genetically engineer immune cells into potent weapons for battling HIV 2Health News:Einstein researchers genetically engineer immune cells into potent weapons for battling HIV 3Health News:AANA Condemns Unsafe Injection Practices 2Health News:AANA Condemns Unsafe Injection Practices 3Health News:AANA Condemns Unsafe Injection Practices 4Health News:AANA Condemns Unsafe Injection Practices 5Health News:Pharos Innovations Announces First Recipient of National Award for Achievements in Chronic Care Programs and Research 2Health News:Pharos Innovations Announces First Recipient of National Award for Achievements in Chronic Care Programs and Research 3Health News:Rheumatoid Arthritis Drugs May Lower Heart Attack, Stroke Risk 2
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
Medicine Products: